PAVE Library: relevant scientific publications and media coverage

**WEBSITE**

- *P. vivax* information hub
- Vivax malaria Study Database
- Tafenoquine Roll-Out Study (TRuST)

**SCIENTIFIC PUBLICATIONS**

**Publications on Radical Cure:**
- Towards the elimination of *Plasmodium vivax* malaria: Implementing the radical cure
- The prevention and treatment of *Plasmodium vivax* malaria
- Primaquine for *Plasmodium vivax* radical cure: What we do not know and why it matters
- Malaria Journal: Challenges for achieving safe and effective radical cure of *Plasmodium vivax*: a round table discussion of the APMEN Vivax Working Group

**Publications on Radical Cure in Latin America:**
- Towards one standard treatment for uncomplicated *Plasmodium falciparum* and *Plasmodium vivax* malaria: Perspectives from and for the Peruvian Amazon

**Evidence on primaquine:**
- Efficacy of 3 Regimens of Chloroquine and Primaquine for Treatment of *P. vivax* Malaria, Cruzeiro do Sul, Acre, Brazil (*pending final publication*)
- Malaria Journal: Quantifying primaquine effectiveness and improving adherence: a round table discussion of the APMEN Vivax Working Group

**Evidence on tafenoquine:**
- New England Journal of Medicine: Tafenoquine – A Radical Improvement?
- New England Journal of Medicine: Single- Dose Tafenoquine to Prevent Relapse of *Plasmodium vivax* Malaria
- New England Journal of Medicine: Tafenoquine versus Primaquine to Prevent Relapse of *Plasmodium vivax* Malaria
- A Pharmacokinetics, Safety and Efficacy Study of Tafenoquine (TQ) in Pediatric Subjects with *Plasmodium Vivax (P. vivax)* Malaria (*pending final publication*)
**Additional publications on tafenoquine:**

- PloS Medicine: Estimated impact of tafenoquine for *Plasmodium vivax* control and elimination in Brazil: A modelling study
- PloS Medicine: Global economic costs due to vivax malaria and the potential impact of its radical cure: A modelling study
- Cochrane Library: Tafenoquine for preventing relapse in people with *Plasmodium vivax* malaria
- Journal of Travel Medicine: Tafenoquine and G6PD: a primer for clinicians
- Current Opinion in infectious diseases: Tafenoquine: the new kid on the block

**Evidence on the G6PD test:**

- American Journal of Trop. Medicine and Hygiene: Evaluation of a Novel Quantitative Test for Glucose-6-Phosphate Dehydrogenase Deficiency: Bringing Quantitative Test for Glucose-6-Phosphate Dehydrogenase Deficiency Closer to the Patient
- PloS One: Field evaluation of quantitative point of care diagnostics to measure glucose-6-phosphate dehydrogenase activity
- PLOS Neglected Tropical Diseases: Evaluation of a point-of-care diagnostic to identify glucose-6-phosphate dehydrogenase deficiency in Brazil

**Additional publications on the G6PD test:**

- International Journal of Neonatal Screening: Point-of-care Testing for G6PD Deficiency: Opportunities for Screening
- Malaria Journal: Usability of a point-of-care diagnostic to identify glucose-6-phosphate dehydrogenase deficiency: a multi-country assessment of test label comprehension and results interpretation
- PloS: Neglected Tropical Diseases: Real-life implementation of a G6PD deficiency screening qualitative test into routine vivax malaria diagnostic units in the Brazilian Amazon (SAFEPRIM study)

---

**EVIDENCE BRIEFS**

- Pediatric treatment for *P. vivax* malaria: new positive data
- New treatment for *P. vivax* malaria may benefit Brazilian public health
- Evaluation of a point-of-care test for G6PD deficiency in Brazil
New Partnership launched to accelerate elimination of relapsing *P. vivax* malaria that poses a risk to an estimated 2.5 billion people worldwide

Partnership for Vivax Elimination (PAVE) Feasibility Studies and Operational Research

PATH and MMV launch 5-year global initiative to support elimination of relapsing malaria

What does it take to eliminate malaria?

Preparing the ground in the Brazilian Amazon

New medicine to treat malaria starts to be used in Amazonas

PATH and SDB announce partnership to advance diagnostic test critical for malaria treatment and elimination

US FDA approves Krintafel (tafenoquine) for the radical cure of *P. vivax* malaria

Kozenis (tafenoquine) approved by Australian TGA for the radical cure of *P. vivax* malaria

Brazil becomes first malaria-endemic country to approve single-dose tafenoquine (Kozenis) for radical cure of *P. vivax* malaria

New single-dose medicine to prevent relapse of *P. vivax* malaria just approved in Peru

First real-world use of new protocol for *P. vivax* case management in Brazil – a Health Ministry and MMV collaboration